|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Catumaxomab (CATU) is a trifunctional antibody approved for intraperitoneal (i.p.) treatment of malignant ascites (MA) related to carcinomas expressing the epithelial cell-adhesion molecule (EpCAM).
|
26417039 |
2015 |
|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The epithelial glycoprotein-2 (EGP-2) promoter is active in a broad variety of carcinomas, the most common type of cancer.
|
17137670 |
2007 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Because of its expression pattern and molecular function, EpCAM is a valuable target in prognostic and therapeutic approaches for various carcinomas.
|
29700109 |
2018 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The human pancarcinoma-associated epithelial glycoprotein-2 (EGP-2), also known as 17-1A or Ep-CAM, is a 38-kDa transmembrane antigen, commonly used for targeted immunotherapy of carcinomas.
|
10473805 |
1999 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The mAb KS1/4 recognizes a novel cell surface glycoprotein on a variety of epithelial carcinomas which may be a useful target Ag for antibody-directed diagnostic and therapeutic approaches.
|
2469722 |
1989 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The human pancarcinoma-associated epithelial glycoprotein-2 (EGP-2), a M(r) 38,000 transmembrane antigen also known as 17-1A or Ep-CAM, is commonly used for targeted immunotherapy of carcinomas because it is strongly expressed by most carcinomas.
|
11358833 |
2001 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
As these EGP-2 sequences can confer promoter activity to reporter and suicide genes in an EGP-2 restricted manner, they may be useful for gene therapy of EGP-2 expressing carcinomas.
|
15243630 |
2004 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Defined by monoclonal antibody GA733, the GA733-2 antigen is a cell surface 40-kDa glycoprotein associated with human carcinomas of various origins.
|
2333300 |
1990 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The EpCAM promoter fragment is, thus, a novel tool to allow for the transcription of therapeutic genes, specifically, in EpCAM-positive carcinomas.
|
15736402 |
2005 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The epithelial cell adhesion molecule (EpCAM) is a transmembrane protein associated with a variety of carcinomas, where EpCAM is often strongly up-regulated or, as in the case of squamous cell carcinomas, de novo expressed.
|
12926061 |
2003 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Additionally, E-FABP levels correlated with the amount of EpCAM in permanent squamous cell carcinoma lines and in vivo in primary head and neck carcinomas.
|
15922867 |
2005 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The superior reactivity of chimeric 323/A3 with EGP40 on carcinoma cells and its higher cytotoxicity-mediating capacity, compared to chimeric 17-1A, are important characteristics, which support further clinical studies with chimeric MAb 323/A3 in immunotherapy of carcinomas.
|
8137290 |
1994 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
After designing and developing a large number of bsAbs for years, catumaxomab, a full-length bsAb targeting EpCAM and CD3, was approved in 2009 to treat EpCAM-positive carcinomas besides blinatumomab, a bispecific T cell engager antibody targeting CD19 and CD3, which was approved in 2014 to treat relapsed or refractory acute lymphoblastic leukemia.
|
31011631 |
2019 |
|
Carcinoma
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
Expression of the epithelial cell adhesion molecule EpCAM is upregulated in a variety of carcinomas.
|
19002182 |
2008 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The epithelial cell adhesion molecule (EpCAM) is overexpressed on most carcinomas.
|
23403823 |
2013 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Epithelial cell adhesion molecule (EpCAM) is a cancer stem cell (CSC) marker that is expressed in various epithelial carcinomas, including EAC.
|
30116994 |
2018 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Taking this rather ubiquitous expression of EpCAM in carcinomas and TICs into account, the question arises how EpCAM can serve as a reliable marker for tumor-initiating cells and what might be the advantage for TICs to express this molecule.
|
22647938 |
2012 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The epithelial cell adhesion molecule (EpCAM) is a membrane glycoprotein that is expressed in most normal human epithelia and overexpressed in most carcinomas.
|
23264216 |
2012 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Epithelial cell adhesion molecule (EpCAM) is a type I transmembrane glycoprotein overexpressed in human epithelioma but with relatively low expression in normal epithelial tissues.
|
25960617 |
2015 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
EpCAM (epithelial cell adhesion molecule) is a cell surface molecule that is known to be highly expressed in colon and other epithelial carcinomas.
|
15313925 |
2004 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Epithelial glycoprotein 40 (EGP40) is a homophilic cell-cell adhesion molecule and expressed on the surface of most simple epithelial cells and the majority of carcinomas.
|
11205703 |
2001 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The GA733 gene family is composed of GA733-1 (TROP2) and GA733-2 (Ep-CAM), whose expression has been examined in various carcinomas and reported to be significantly associated with prognosis.
|
20473768 |
2010 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The human epithelial cell adhesion molecule (EpCAM) is expressed on normal epithelial cells and is overexpressed in most carcinomas.
|
15634917 |
2005 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Therefore, we developed bispecific PARs that selectively target the human CD3 receptor and human epithelial cell adhesion molecule (EpCAM), which is overexpressed on multiple carcinomas and cancer stem cells.
|
29792808 |
2018 |